Research and Markets (http://www.researchandmarkets.com/research/a4c187/romania_pharmaceut) has announced the addition of the “Romania Pharmaceuticals and Healthcare Report Q3 2008” report to their offering.
Our Romania Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Romania’s pharmaceuticals and healthcare industry.
In our adjusted Business Environment Rankings for Central & Eastern Europe (CEE) for Q308, Romania is found in a joint ninth position, on a par with Slovenia. The country’s pharmaceutical rating, which corresponds to the region’s average, masks the strong forecast growth of in the first half of the forecast period. Key weaknesses of the market include chronic funding shortages, which have resulted in severe payment delays, cumbersome bureaucracy and widespread corruption.
On a positive note, from the start of April 2008, new legislation stipulates that doctors need to prescribe specific brands rather than international non-proprietary names (INN’s), which will stimulate the growth of the branded market. The requirement should also allow wholesalers and pharmacies to continue enjoying the larger profit margins from branded medications. However, this could be off-set by the government’s current price structuring programme, which – by not accurately reflecting currency fluctuations – is decreasing profit margins on imported goods.
In fact, in February 2008, the Romanian association of pharmaceutical distributors and importers (ADIM) called for more flexibility to increase drug prices in order to offset the impact of a depreciating currency. Under current regulations, prices are adjusted according to exchange rates every three months, although – in practice – the increases have not been granted for months. Consequently, importers have warned that they will be forced to cease trading if nothing is done, which could have a severe impact on the market, as imports account for around two-thirds of drug expenditure.
Nevertheless, the Romanian pharmaceutical market is increasingly being targeted by Indian generics markers. In March 2008, India-based Glenmark Pharmaceuticals established a new subsidiary in Romania, Glenmark Pharmaceuticals s.r.l, boosting its presence in CEE to three countries in total. In the preceding months, Indian Lupin, Dr Reddy’s Laboratories and Shreya Lifesciences had been linked to a potential purchase of local generics producer LaborMed, following the lead of Ranbaxy, which now owns Terapia. However, the LaborMed Pharma Group was acquired by US investment fund Advent International, which is planning to modernise business processes, strengthen the company’s portfolio and brand image, as well as expand through local and regional acquisitions.
Key Topics Covered:
– Romania Pharmaceuticals And Healthcare Industry SWOT
– Romania Business Environment SWOT
– Pharmaceutical Business Environment Ratings
– Limits To Potential Returns
– Risks To Potential Returns
– Romania – Market Summary
– Regulatory Regime
– Recent Pricing And Reimbursement Developments
– Industry Developments
– Health Status
– Pharmaceutical Industry
– Domestic Industry Developments
– Foreign Industry Developments
– Medical Devices
– Patented Market Forecast
– Generics Market Forecast
– OTC Market Forecast
– Export/Import Forecasts
– Other Healthcare Data Forecasts
– Key Risks To BMI’s Forecast Scenario
– Competitive Landscape
– Our Forecast Modelling
Companies Mentioned:
– Actavis Romania (Sindan)
– Antibiotice Iasi
– GlaxoSmithKline (Europharm)
– Krka
– LaborMed Pharma
– Merck & Co
– Novartis
– Ozone Laboratories
– Pfizer
– Roche
– Sanofi-Aventis
– Terapia-Ranbaxy
– Zentiva (incorporating Sicomed)
For more information visit http://www.researchandmarkets.com/research/a4c187/romania_pharmaceut
Comments